Oncology Diagnostics Panel Session

Kineticos recently hosted a panel with 3 industry veterans to gain insight regarding the nuances of the oncology diagnostics market.  The first installment touched on new, exciting technologies while Part 2 contains insight from our panelists regarding what diagnostic companies can do to monetize their technologies in a time where reimbursement is poor.

Panel Members

  • Eric Mayer, CEO, EDP Biotech
  • Sandra Dunn, CEO, Phoenix Molecular
  • Brian Kelly, Global Director, Diagnostic Partnering, Thermo Fisher

Click here for a condensed and edited version of Part 2.

Subscribe to Kineticos to receive weekly emails containing insightful content.